3-(Methylamino)piperidine Dihydrochloride

We are 3-(Methylamino)piperidine Dihydrochloride CAS:127294-77-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  3-(Methylamino)piperidine Dihydrochloride
CAS.NO:127294-77-3
Molecular Formula:C6H16Cl2N2
Molecular Weight:187.11100

Synonyms:
N-methylpiperidin-3-amine,dihydrochloride
3-(Methylamino)piperidine dihydrochloride
N-Methylpiperidin-3-amine dihydrochloride
3-Methylaminopiperidine dihydrochloride

Physical and Chemical Properties:
Density: /
Boiling point: 253.7ºC at 760 mmHg
Melting point: 199-200°C
Flash point: 107.2ºC
Refractive index: /

Specification:
Appearance:White  powder
Purity:≥99.0%
Moisture Content: 0.25%
Impurity: 0.3%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:3-Methylaminopiperidine dihydrochloride is an intermediate for the production of a new generation of quinolone antibiotics, baloxafloxacin.

3-(Methylamino)piperidine Dihydrochloride


Related News: “We will continue to closely monitor the situation and we look forward to reopening our stores as soon as possible.”1,4'-bipiperidine Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.2,2,3,3-tetramethylcyclopropanecarboxylic acid Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.2-bromo-5-methyl-3-nitropyridine CAS:23056-46-4 Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.

Related Products
Product Name
1,3-Bis(2,4-Diaminophenoxy)Propane 4HCl View Details
(S)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylic acid View Details
N-(4-(9-phenyl-9H-fluoren-9-yl)phenyl)-[1,1′-biphenyl]-4-amine View Details
Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate manufacturer 1-(benzotriazol-1-yl)octan-1-one manufacturer 2-(7-Methoxynaphthalen-1-yl)ethanamine manufacturer (Z)-Guggulsterone manufacturer 4,4,4-Trifluoro-1-(4-methylphenyl)butane-1,3-dione manufacturer